The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Analyzing patterns of disease failure in patients with primary CNS lymphoma
Kathryn Tringale, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses a study which analyzed patterns of disease failure in a large cohort of patients with primary CNS lymphoma. Nearly all patients received methotrexate-based induction therapy, and 385 patients in this cohort received consolidation therapy. Results demonstrated that patients who experienced early relapse were more likely to fail at the original site of disease, whereas those who underwent consolidation therapy had unpredictable and distant relapses, suggesting a potential role for local treatment in this high-risk subgroup of patients. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
